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whose blood expression was altered compared to healthy subjects. In OA, 9
miRNA were up-regulated (including miR-228, miR-574-3p, miR-597) and
9 miRNAs were down-regulated (including miR-150, miR-222, miR-363
and miR-423). None of miRNAs in OA is common with those we found
in RA. Potential targets of miRNAs, speciﬁcally expressed in severe knee
osteoarthritis, appears to be largely involved in the Wnt signaling pathway.
In contrast, the miRNAs expressed differently in the blood of our RA
patients seem to target the elements of the signaling pathway MAP kinase.
Conclusions: Our results suggest that miRNAs may constitute new
biomarkers potential diagnostic interest. In addition, miRNAs could be
involved in the pathogenesis of OA. Further work is ongoing in order to
assess the pathophysiological and the functional role of these miRNAs in
OA.
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STATIN USE IS ASSOCIATEDWITH REDUCED INCIDENCE AND
PROGRESSION OF KNEE OSTEOARTHRITIS
S. Clockaerts1,2 , B. Stricker2, Y.M. Bastiaansen-Jenniskens2, F. Van
Glabbeek1, J.B. Van Meurs2, J.A. Verhaar2, A. Hofman2, G.V. Van Osch2,
S.M. Bierma-Zeinstra2
1Univ. of Antwerp, Edegem, Antwerp, Belgium; 2Erasmus MC, Univ. Med. Ctr.,
Rotterdam, Netherlands
Purpose: Besides biomechanical and genetic alterations, the pathogenesis
of osteoarthritis (OA) may involve inﬂammation, vascular alterations and
dysregulation of lipid metabolism. Statins are drugs capable of modulating
many of these different mechanisms and therefore may have the potential
to act as disease modifying drugs for osteoarthritis. In this study we
hypothesized that statins decrease incidence and progression of knee and
hip OA. To test this hypothesis, we used a large population cohort study.
Methods: 2974 subjects of the Rotterdam Study (a population-based cohort
study), aged 55 years and older were included in this study. X-rays of
the knee and the hip were obtained at baseline and follow up (mean
follow up 6.3 years), and were scored with the Kellgren & Lawrence score
(0=absent OA, 1=doubtful OA, 2=mild OA, 3=moderate OA, 4=severe OA, 5=
prosthesis). Incidence of OA was deﬁned as a Kellgren & Lawrence score
of 0 or 1 and a score of 2 or more at follow up. Progression of OA was
speciﬁed as a Kellgren & Lawrence score of 1, 2 or 3 and increase of 1 or
more. Information on statin use was obtained from detailed computerized
pharmacy data. Use of statins was deﬁned as the daily use of 50% or more
of recommended dose and this for a period of 100 days or more. Data
on potential confounding variables such as age, gender, body mass index,
diabetes mellitus, arterial hypertension, peripheral artery disease, bone
mineral density and total cholesterol level were collected. A multivariate
logistic regression model adjusting for confounding variables was ﬁtted to
calculate odds ratios with conﬁdence intervals. Correlations between right
and left joints were accounted for with generalized estimating equations.
Results: Osteoarthritis (Kellgren & Lawrence score 2 or more) was present
in 546 knees and 323 hips at baseline and in 696 knees and 521 hips at
follow up in 1277 men and 1697 women. Overall, 13.2% of subjects were
deﬁned as statin users. The adjusted odds ratios for incidence of knee OA
in users of statins was 0.40 (95% CI 0.20 - 0.80, p=0.01) and for progression
of knee OA 0.47 (95% CI 0.25 - 0.87, p=0.02). The use of statins was neither
associated with incidence of hip OA (adjusted odds ratio 0.85, 95% CI 0.54 -
1.34, p=0.48), nor with progression of hip OA (adjusted odds ratio 1.13, 95%
CI 0.71 - 1.81, p=0.61).
Conclusions: Statin use is associated with a reduction in incidence and
progression of knee osteoarthritis. Randomized clinical trials in a popula-
tion at risk are needed to examine whether statins could be useful as a
treatment for knee OA.
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EIGHTY-SEVEN PERCENT OF 66 ADULT PATIENTS WITH ADVANCED
OSTEOARTHRITIS OF THE KNEE SUBJECTED TO TREATMENTWITH
INTRA-ARTICULAR INJECTIONS OF HUMAN GROWTH HORMONE AVOID
TOTAL KNEE ARTHROPLASTY
A.R. Dunn
Mt. Sinai Med. Ctr., Miami Beach, FL
Purpose: Intra-articular injections of growth hormone produce Pre-natal
Developmental Healing (PDH). This unique action of growth hormone,
proven in mature rabbits, does not involve bleeding, clot formation or the
in-pouring of inﬂammatory cells. This healing is scar-free and produces
no ﬁbroartilage. The cascade of PDH ﬁrst involves the rejuvenation of
mature subchondral arteries to form fetal fenestrated capillaries which
produce autologous stem cells. These are the same vessels which produce
the fetal cartilage skeleton in utero. These stem cells are signaled to form
chondrocytes and by the completion of the PDH cascade real articular
cartilage with vertical parallel columns of chondrocytes form with arcades
at the surface and 100 per cent bonding to host bone. This method is the
ﬁrst to regrow real articular cartilage.
Method: Sixty-six adults with advanced osteoarthritis of the knee were
treated with intra-articular injections of Human Growth Hormone (HGH).
One-third required arthroscopic debridement and abrasion of eburnated
bone on the condyles.
Each knee received from eight to ﬁfteen weekly injections of Human
Growth Hormone (HGH). Dosage varied according to the size of the knee.
All patients were required to be non weight bearing on the treated side for
the duration of the treatment. Patients were required to perform simple
exercises at home. Less than one-fourth required physiotherapy.
There were no complications or side effects from the surgery or the
injections of human growth hormone (HGH)
Results: Eighty-seven percent of the patients had good to excellent results.
Several before and after X-rays of the HGH treated knees will be presented.
These X-rays demonstrate an increase of the joint spaces from 2 to 5 mm.
Evaluation with the IKDC format will be presented in graph form. There
were no infections, complications, side effects, deep vein thrombosis, pul-
monary embolism or deaths. The patients who did not respond were no
worse. Six per cent went on to have total knee arthroplasty (TKA). the
remainder were undecided about having TKA.
Conclusions: A safe, cost-effective alternative to TKA is presented. There
were no complications such as those which arise from TKA. The cost of
treatment with HGH even including arthroscopic surgery is one-fourth that
of TKA. And the additional costs of treating infected TKA are completely
avoided. Many orthopedic surgeons are concerned that their livelihood
will be adversely impacted by loss of TKA surgery; however, they should
consider that there is no need for hospital rounds, or need to treat infec-
tions and other serious complications. Insurance companies and Medicare
or other government insurance programs can save billions of dollars every
year by avoiding costly TKA surgeries at $35,000.00 per TKA.
The author recommends that this HGH treatment, which he named IAGH,
be the ﬁrst choice for treating advanced osteoarthritis of the knee.
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EFFECT OF ROSEMARY EXTRACT AND RELATED FLAVONOID CARNOSOL
ON CHONDRO-PROTECTION AND ON THE BONE-CARTILAGE CROSSTALK
M.-N. Horcajada1, C. Sanchez2, F. Scalfo1, L. Ameye1, Y. Henrotin2,
E. Offord1
1Nestle, Lausanne, Switzerland; 2Univ. of Liège, Liège, Belgium
Purpose: The aim of this work was to evaluate the effect of Rosemary
extract (P31, Robertet, France) and one of its associated ﬂavonoids, carnosol
(Sigma, Buchs, Switzerland) on metabolic functions of chondrocytes and
osteoblasts, as well as on the bone-cartilage crosstalk.
Methods: Content of carnosol in rosemary extract P31 was around 7%.
Rosemary extract and carnosol eﬃcacy were assessed at various concentra-
tions in the different experiments: 3-25μg/ml and 6nM-30μM, respectively.
Normal and Osteoarthritic (OA) human chondrocytes were cultured in al-
ginate beads for 12 days in presence or absence of both compunds.
Production of aggrecan (AGG), stromelysin (MMP-3), interleukin (IL)-6 and
nitric oxide were analyzed. Isolated human osteoblasts from sclerotic (SC)
or non sclerotic (NSC) subchondral bone were cultured for 3 days in
presence or absence of both compounds and alkaline phosphatise (AP)
activity, interleukin-6 and prostaglandin PGE2 levels were determined.
Finally, subchondral osteoblasts coming from NSC or SC areas were incu-
bated with rosemary extract or carnosol for 72h before coculture with OA
chondrocytes in alginate beads. After 4 days of co-culture, we analyzed
AGG content of the alginate beads, and chondrocytes gene expression of
AGG, type II collagen, MMP-3, MMP-13 and osteopontin (OPN).
Results: In both OA and normal chondrocytes, AGG production was signif-
icantly increased with 9 μM carnosol. MMP-3 and nitric oxide production
was signiﬁcantly decreased by both compounds, in a dose-dependent
manner, while only carnosol signiﬁcantly decreased the cytokine IL-6
secretion. Regarding osteoblast cultures, AP activity was not affected in the
